EP3565641B1 - Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau - Google Patents

Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau Download PDF

Info

Publication number
EP3565641B1
EP3565641B1 EP18709138.4A EP18709138A EP3565641B1 EP 3565641 B1 EP3565641 B1 EP 3565641B1 EP 18709138 A EP18709138 A EP 18709138A EP 3565641 B1 EP3565641 B1 EP 3565641B1
Authority
EP
European Patent Office
Prior art keywords
soluble film
product
zone
skin
water soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18709138.4A
Other languages
German (de)
English (en)
Other versions
EP3565641A1 (fr
Inventor
Emily Charlotte Boswell
Jack Alan HUNTER
Elizabeth Anne Wilder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP3565641A1 publication Critical patent/EP3565641A1/fr
Application granted granted Critical
Publication of EP3565641B1 publication Critical patent/EP3565641B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
    • A61F13/025—Adhesive bandages or dressings characterised by the skin-adhering layer having a special distribution arrangement of the adhesive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00285—Wound bandages medication confinement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Definitions

  • the present invention relates to products comprising a barrier patch and soluble film zones comprising skin active agents for improving skin appearance.
  • the present invention also relates to a method of delivering cosmetic compositions to a target area of the skin via the use of such product.
  • Certain beauty care patch systems comprise an active reservoir in which the active is present in solid, liquid or dissolved form and a layer of pressure-sensitive adhesive by which the system can be brought into close contact with the skin. These systems are limited when the active does not diffuse through the adhesive layer, when a chemical reaction occurs between the active and the adhesive, or when the active is insoluble or only poorly soluble in the adhesive.
  • the product comprises a soluble film zone comprising a cosmetic composition comprising a skin active agent and a water soluble film forming polymer, wherein the soluble film zone or product is capable of changing from a first visual state to a second visual state.
  • the product thus provides a signal during use so that the consumer is aware that an effective amount of the active ingredient is provided and released to the skin and thus that the product is effective.
  • This product may also comprise a pressure sensitive adhesive that is substantially separate from the active ingredients so that any interaction between the two is minimized.
  • the present invention solves at least one of these problems by incorporating at least one soluble film zone into a beauty care product and the soluble film is directed, in part, to having the correct degree of solubility.
  • a multi-layered beauty care product for applying a skin active agent to the skin comprising:
  • a multi-layered beauty care product for applying a skin active agent to the skin comprising:
  • a multi-layered beauty care product for applying a skin active agent to the skin comprising:
  • the adhesive zone is continuous and the soluble film zone may be continuous or discontinuous.
  • the beauty care product may be applied to any keratinous tissue.
  • molecular weight refers to the weight average molecular weight unless otherwise stated. Molecular weight is measured using industry standard method, gel permeation chromatography ("GPC").
  • compositions of the present invention can comprise, consist essentially of, or consist of, the essential components as well as optional ingredients described herein.
  • “consisting essentially of' means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
  • applying means to apply or spread the compositions onto a substrate such as the human skin surface or epidermis.
  • compositions or components thereof so described are suitable for use in contact with mammalian keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like.
  • facial skin surface refers to one or more of forehead, periorbital, cheek, perioral, chin, and nose skin surfaces. While facial skin surfaces are of concern and are exemplified herein, other skin surfaces may be treated with the compositions and methods of the present invention, for example, surfaces typically not covered by clothing such as facial skin surfaces, hand and arm skin surfaces, foot and leg skin surfaces, and neck and chest skin surfaces (e.g., Vietnameselletage).
  • health skin means that the physical barrier function of the epidermis and the dermis is maintained intact for example, the stratum corneum of skin is intact, and is not physically disrupted, removed, subject to reduction, wounded, altered or ablated using mechanical, optical, or thermal means.
  • keratinous tissue refers to keratin-containing layers disposed as the outermost protective covering of mammals (e.g., humans, dogs, cats, etc.) which includes, but is not limited to, skin, mucosa, lips, hair, toenails, fingernails, cuticles, hooves, etc.
  • topical application means to apply (e.g., spread, spray) the compositions of the present invention onto the surface of the keratinous tissue.
  • an effective amount means an amount of a compound or composition sufficient to significantly induce a positive keratinous tissue benefit, including independently or in combination with other benefits disclosed herein. This means that the content and/or concentration of agent in the formulation is sufficient that when the formulation is applied with normal frequency and in a normal amount, the formulation can result in the treatment of one or more undesired keratinous tissue conditions (e.g., skin wrinkles). For instance, the amount can be an amount sufficient to inhibit or enhance some biochemical function occurring within the keratinous tissue. This amount of the skin care agent may vary depending upon the type of product, the type of keratinous tissue condition to be addressed, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive keratinous tissue appearance, including independently or in combinations with the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • water impermeable includes materials or objects through which water in its liquid state does not pass.
  • substantially free of' refers to an amount of a material that is less than 2%, 1%, 0.5%, 0.25%, 0.1%, 0.05%, 0.01%, or 0.001% by weight, of product, the barrier patch, the water soluble film zone, the water soluble film forming polymer, or the backing layer of the barrier patch. "Free of' refers to no detectable amount of the stated ingredient or thing.
  • Bio-based content refers to the amount of carbon from a renewable resource in a material as a percent of the mass of the total organic carbon in the material, as determined by ASTM D6866-10, Method B. Note that any carbon from inorganic sources such as calcium carbonate is not included in determining the bio-based content of the material.
  • Biodegradation refers to a process of chemical dissolution of materials by microorganisms or other biological means.
  • Bio-identical polymer refers to polymers that are made from monomers where at least one monomer is derived from renewable resources. For instance, a bio-identical polyolefin is made from olefins that are derived from renewable resources, whereas a petro-based polyolefin is made from olefins typically derived from non renewable oil or gas.
  • Bio-new polymer refers to polymers that are directly derived (i.e., no intermediate compound in the derivation process) from renewable resources.
  • renewable resources include cellulose (e.g. pulp fibers), starch, chitin, polypeptides, poly (lactic acid), polyhydroxyalkanoates, and the like.
  • “Monomeric compound” refers to an intermediate compound that may be polymerized to yield a polymer.
  • nonwoven means a porous, fibrous material made from continuous (long) filaments (fibers) and/or discontinuous (short) filaments (fibers) by processes such as, for example, spunbonding, meltblowing, carding, and the like.
  • Nonwoven webs do not have a woven or knitted filament pattern.
  • Petroleum refers to an organic compound derived from petroleum, natural gas, or coal.
  • Crude oil refers to crude oil and its components of paraffinic, cycloparaffinic, and aromatic hydrocarbons. Crude oil may be obtained from tar sands, bitumen fields, and oil shale.
  • Polymers derived directly from renewable resources refer to polymers obtained from a renewable resource without intermediates. Typically, these types of polymers would tend be "bio-new”.
  • Post-consumer recycled polymers refer to synthetic polymers recovered after consumer usage and includes recycled polymers from plastic bottles (e.g., laundry, milk, and soda bottles).
  • Renewable resource refers to a natural resource that can be replenished within a 100 year time frame.
  • the resource may be replenished naturally, or via agricultural techniques.
  • Renewable resources include plants, animals, fish, bugs, insects, bacteria, fungi, and forestry products. They may be naturally occurring, hybrids, or genetically engineered organisms. Natural resources such as crude oil, coal, and peat which take longer than 100 years to form are not considered to be renewable resources.
  • the water soluble film zone comprises a water soluble film forming polymer and a cosmetic composition comprising an effective amount of a skin active agent.
  • the water soluble film forming polymer forms a water soluble film preferably selected from the group of water soluble films that also comprise a solubility defined by an Opacity Change Index of about 2.5 to about 50 according to the Opacity Test Method herein.
  • water-soluble film means a film that dissolves according to the dissolution method herein.
  • the water soluble film zone comprises from about 30% to about 99% or from about 40% to about 90%, more preferably from about 50% to about 75% of a water soluble film forming polymer such as polyethylene oxide, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, and combinations thereof.
  • a water soluble film forming polymer such as polyethylene oxide, methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, and combinations thereof.
  • a "low water environment" of the skin means the humidity or moisture provided, under occlusion, from the inner skin layer(s) of healthy skin to the surface of the skin via the pores in the skin. This may comprise components of sweat, sebum or oil.
  • a low water environment includes the humidity build up on the skin when the product herein is applied to the skin for about 1 to 8 hours or longer, the product comprising a backing layer having a low breathability (e.g. low WVTR, the proper thickness, etc.), as provided herein.
  • the soluble films herein are capable of changing from a first visual state to a second visual state wherein the first visual state comprises a first opacity and the second visual state comprises a second opacity that is lower than the first opacity; and the change in opacity is capable of being observed by a consumer.
  • the change from a first visual state to a second visual state is represented by an Opacity Change Index of the water soluble film herein and is from about 2.5 to about 50, or from about 3 to about 40 or from about 5 to about 20 or from about 2.5 to about 45 or about 3 to about 45.
  • the soluble film zone comprises a skin active agent wherein the skin active agent is only minimally released, if at all, from the soluble film zone in the dry form prior to use and/or prior to exposure to the low water environment and/or in the absence of humidity or water.
  • the skin active agent is only minimally released, if at all, from the soluble film zone in the dry form prior to use and/or prior to exposure to the low water environment and/or in the absence of humidity or water.
  • humidity contacts the soluble film zone, softening, dissolution or breakdown, begins to occur, thereby enabling the skin active to migrate out of the soluble film zone and/or penetrate to the skin surface or into the skin.
  • skin active agents present in the soluble film zones are believed to be more readily available to the skin due to the faster rates of diffusion through the soluble film zone.
  • the soluble film zone or product is thus capable of changing from a first visual state to a second visual state wherein the first visual state comprises a first opacity and the second visual state comprises a second opacity that is lower that first opacity.
  • the skin active agent may be released from the product to the skin of the user and be absorbed into the skin to have the intended effect.
  • Figure 10 shows a table with the Opacity Change Index for several samples of water soluble film comprising polyethylene oxides.
  • the water soluble film or film zone dissolves, disintegrates, and/or loses its physical integrity when exposed to low water environments.
  • the water soluble film prior to exposure to a low water environment is a dry film comprising a water soluble film forming polymer and where the polymer exists in a solid, semi-crystalline form with high enough % crystallinity with crystallites present that refract light in a particular way.
  • crystallinity changes to create a different refraction of light, for example less crystallites to refract light, such that a visible change in opacity occurs.
  • the oil in water or water in oil emulsion has an initial opacity of from about 10 to about 100, preferably from about 10 to about 70, or from about 12 to about 65, or from about 14 to about 50.
  • the opacity or initial opacity may be provided in the water soluble film zone from the crystalline structure of the water soluble polymer. It may also be provided from the structure of the emulsion such as from the droplets of the emulsion, e.g. the dispersed oil phase droplets in an oil in water emulsion, wherein the droplets interfere with the pathway of light. Without being limited by theory these droplets are trapped inside the film zone.
  • the particles or droplets are crystalline and may be derived from, for example, the wax phase of the skin cream emulsion.
  • Various cosmetic compositions comprising emulsions are disclosed in US 5,972,359, Sine et al., issued on Oct. 26, 1999 .
  • the water soluble film zone prior to use by the consumer, is substantially free of water or may comprise less than 15%, less than 12%, or less than 10%, water, or comprise about 0.001% to about 15% water, or about 0.05% to about 10%, water, or about 0.05% to about 3%, water, by weight of the soluble film zone.
  • Preferred water-soluble materials for the soluble film zone are polymeric materials, preferably polymers which may be formed into a film or sheet.
  • the water-soluble film zone can, for example, be obtained by casting, blow-molding, extrusion or blown extrusion of the polymeric material, as known in the art.
  • Preferred polymers, copolymers or derivatives thereof suitable for use as water-soluble film for the soluble film zone are selected from polyethylene oxides, methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and combinations thereof.
  • Preferred water-soluble films are made from polyethylene oxides such as polyethylene oxide films or polyethylene glycol, include Polyox, sold by the Dow Chemical Company.
  • Polyethylene oxides include Polyox WSR N-10 (having a molecular weight of 100,000), WSR N-80 (with a molecular weight of about 200,000), WSR N750 (with a molecular weight of about 300,000), WSR-205 (with a molecular weight of about 600,000), WSR-1105 (with a molecular weight of about 900,000), of corresponding solubility characteristics.
  • the water soluble film comprises a polyethylene oxide having a molecular weight from about 500 to about 10,000,000 or from about 10,000 to about 1,000,000 or from about 100,000 to about 300,000 or from about 150,000 to about 250,000.
  • plasticized methylcellulose and/or plasticized hydroxypropyl methylcellulose and/or plasticized hydroxypropylcellulose comprise plasticized methylcellulose and/or plasticized hydroxypropyl methylcellulose and/or plasticized hydroxypropylcellulose.
  • plasticized means a composition of methylcellulose or hydroxypropyl methyl cellulose or hydroxypropylcellulose, and plasticizer wherein the plasticizer is used at a level of from about 2% to about 80% or about 2% to about 60%, or from about 10% to about 50% or from about 20% to about 45% by weight of this composition.
  • the hydroxypropyl methylcellulose may be Methocel E5LV, a water soluble cellulose ether of low viscosity available from Dow/Coloron LTD.
  • Methocel grades that may be used include Methocel E3LV, Methocel E6LV, Methocel E15LV, Methocel E50LV, and Methocel K3LV.
  • the polyethylene oxide polymers or methylcellulose or hydroxypropyl methylcellulose or hydroxypropylcellulose polymers may be combined with additional polymers, for example, polymers, copolymers or derivatives thereof which may be other water-soluble film forming polymers.
  • the additional polymers may be selected from polyvinyl alcohols, polyvinyl pyrrolidone, polyalkylene oxides, acrylamide, acrylic acid, cellulose, cellulose ethers, cellulose esters, cellulose amides, polyvinyl acetates, polycarboxylic acids and salts, polyaminoacids or peptides, polyamides, polyacrylamide, copolymers of maleic/acrylic acids, polysaccharides including starch and gelatin, natural gums such as xanthum and carragum, polyacrylates and water-soluble acrylate copolymers, polymethacrylates, methylcellulose, carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, dextri
  • the water soluble film zone comprises polyethylene oxide polymer and an additional polymer selected from the group consisting of polyvinyl alcohols, polyvinyl alcohol copolymers, starch, methylcellulose, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations.
  • polyethylene oxide polymers having different molecular weights.
  • the additional polymers may have molecular weights, preferably from about 1,000 to 1,000,000, more preferably from about 50,000 to 300,000 yet more preferably from about 20,000 to 150,000.
  • the level of water soluble film forming polymer in the water-soluble film zone in the dry state is from about 20% to about 90%, or from about 45% to about 85% or is from about 50% to about 70%.
  • Additional water-soluble materials for the soluble film zone may be selected from polyethylene glycol, pullulan, carbohydrate polymers such as natural polysaccharide or derivates including pectin and derivatives, sodium alginate, methyl methacrylate copolymer, carboxyvinyl polymer, amylase, pectin, chitin, chitosan, levan, elsinan, collagen, gelatine, zein, gluten, soy protein isolate, whey protein isolate, casein, gums (such as guar, gum Arabic, tragacanth gum, xanthan gum, gellan sodium salt, gum ghatti, okra gum, karaya gum, locust bean gum, tara gum, quince seed gum, fenugreek seed gum, scleroglucan, psyllium seed gum, tamarind gum, oat gum, quince seed gum, rhizobium gum, biosynthetic gums, Khaya grandifolia gum,
  • the water soluble film zone comprises a polyethylene oxide and an additional polymer selected from the group consisting of polyethylene oxide polymer, polyvinyl alcohols, polyvinyl alcohol copolymers, starch, methylcellulose, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations.
  • the cosmetic composition may comprise a water in oil or an oil in water emulsion to be combined with a water soluble film forming polymer.
  • a water in water emulsion composition such as Olay skin care product may be combined with polyethylene oxide such as Polyox WSR N-80 or methylcellulose or hydroxypropyl methylcellulose such as Methocel E5LV and used as the water soluble film zone.
  • the water soluble film forming polymer may be used in excess of the composition comprising the oil in water emulsion and skin active agent.
  • the water soluble film zone may comprise:
  • the emulsion used in the present invention may be colored by the use of suitable dyes and pigments.
  • the emulsion may comprise a colorant which may be selected from the group consisting of organic pigments, inorganic pigments, interference pigments, lakes, natural colorants, pearlescent agents, dyes, and mixtures thereof.
  • the pigments, lakes and/or dyes are hydrophobic.
  • Other dyes and pigments are disclosed in International Cosmetic Ingredient Dictionary and Handbook, 10th Edition, Volume 3, 2004, Colorants, pp. 2194-2197 .
  • Opacity of the emulsion may be obtained by dispersing colorants, such as titanium dioxide or white pigments, into the emulsion.
  • Colored pigments provide opacity by absorbing and/or scattering visible light (400 nm-700 nm).
  • Pigments may be dry colorants that are usually ground into a fine powder before incorporation in another material. Pigments may come in different forms, such as white oxide powders which scatter light, or dark colored powders that absorb and scatter light.
  • Titanium dioxide (TiO 2 ) is a multifaceted material when used in applications and has long been established as a leading white pigment.
  • emulsion may comprise a safe and effective amount of a colorant, and/or from about 0.001% to about 5% by weight of the emulsion, of a colorant; in another aspect from about 0.05% to about 3% by weight of the emulsion, of a colorant.
  • the emulsion may comprise fatty alcohols that are for example white waxy solids, such as cetearyl alcohol, cetyl alcohol, myristyl alcohol and behenyl alcohol which are such white, waxy solids.
  • Cetyl alcohol and stearyl alcohol are the two major components of cetearyl alcohol.
  • Other fatty alcohols that may contribute to the opacity function may include those that have a free primary, secondary, or tertiary hydroxyl group attached to a long chain group.
  • Fatty alcohols are usually long chain primary alcohols, but they can also range from as few as 4-6 carbons to as many as 22-26 carbons. They can also be unsaturated and have methyl branching.
  • the emulsion may comprise a safe and effective amount of a fatty alcohol, and/or from about 0.001% to about 30% by weight of the emulsion, or from about 0.001% to about 10%, or in another aspect from about 0.05% to about 5% by weight of the emulsion, of a fatty alcohol.
  • Fig. 12 is an image (20x Bright Field Microscopy) showing an oil in water emulsion with Methocel as the water soluble polymer.
  • Fig. 12 is a combination of Methocel E5LV and an oil in water emulsion, similar to the oil in water emulsion in the Example, at a ratio similar to the ratio in the Example.
  • the structure of the emulsion is shown prior to drying the emulsion into a film. This structure may be maintained upon drying the emulsion into a film as shown in FIG. 13 .
  • the emulsion of FIG. 12 is dried into a film which is shown in Fig. 13 (20x Cross Pol Microscopy).
  • Fig. 13 (20x Cross Pol Microscopy
  • Fig. 13 is a film comprising Methocel and a skin cream comprising an oil in water emulsion.
  • the skin cream particles are dispersed in an amorphous Methocel matrix.
  • Fig. 14 (20x Bright Field Microscopy) shows the film of Fig. 13 after it is exposed to humidity.
  • the Methocel matrix appears solvated with water.
  • the skin cream droplets/spherulites are dispersed throughout.
  • Fig. 15 is an image (20x Bright Field Microscopy) showing PEO in ethanol/water combined with a skin cream comprising an oil in water emulsion similar to the Example. Many of the particles are spherical droplets dispersed in liquid. The droplet diameter is estimated to be approximately 5 ⁇ m to 20 ⁇ m.
  • Figs. 16 (5x Cross Pol Microscopy) and 17 (5x Bright Field Microscopy) show an image of the emulsion of FIG. 15 dried into a film. Similar sized droplets can be observed in the film.
  • the PEO film matrix has large spherulitic crystallites which extend across the entire film.
  • Fig. 18 is an image (5x Cross Pol Microscopy) that shows the film of Figs. 16 and 17 , after 2 hours of saturated humidity treatment. High humidity treatment appears to dissolve the PEO crystallites and makes the sample appear more transparent. PEO matrix becomes isotropic/amorphous due to solvation by water. The skin cream droplets/spherulites are dispersed throughout.
  • Fig. 19 is an image (5x Cross Pol Microscopy) that shows the film of Figs. 18 after it has been re-dried overnight.
  • the water soluble film zone herein can also comprise one or more plasticizers.
  • plasticizers it can be beneficial to add plasticizers at a level of from about 2% to about 80% or about 2% to about 60%, by weight of the soluble film zone or the water soluble film forming polymer, or from about 10% to about 50% or from about 20% to about 45% by weight.
  • the plasticizers may be, for example, glycerol, ethylene glycol, diethylene glycol, hexylene glycol, triethylene glycol, propylene glycol, polyethylene glycol, polypropyl glycol, alkyl citrate, sorbitol, pentaerythritol, glucamine, N-methylglucamine, sodiumcumenesulfonate and mixtures thereof.
  • the plasticizer is glycerol.
  • plasticizers may include vegetable oil, polysorbitols, polyethylene oxide, dimethicone, mineral oil, paraffin, C1-C3 alcohols, dimethyl sulfoxide, N, N-dimethylacetamide, sucrose, corn syrup, fructose, dioctyl-sodium-sulfo-succinate, triethyl citrate, tributyl citrate, 1,2-propylenglycol, mono, di- or triacetates of glycerol, natural gums, citrates, and mixtures thereof.
  • the water soluble film zone or water soluble film forming polymer herein can also comprise one or more optional ingredients.
  • Optional ingredients include bulking agents, fillers, diluents, surfactants, stabilizing agents, emulsifiers, thickeners, preservatives, binders, colorants, pigments, solubilizing agents, wetting agents, water soluble inert fillers, buffering agents, permeation enhancers, and combinations.
  • Thickeners may include gum arabic, carrageenan, karaya gum, gum tragacanth, carob gum, quince seed or Cydonia oblonga, casein, dextrin, gelatin, sodium pectate, sodium alginate, methyl cellulose, CMC, hydroxy ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, PVM, PVP, sodium polyacrylate, carboxy vinyl polymer, locust bean gum, guar gum, tamarind gum, cellulose dialkyl dimethylammonium sulfate, xanthan gum, aluminum magnesium silicate, bentonite, hectorite, AIMg silicate or beagum, laponite, and silicic acid anhydride.
  • Surfactants may include mono and diglycerides of fatty acids and polyoxyethylene sorbitol esters, such as, Atmos 300 and Polysorbate 80, pluronic acid, and sodium lauryl sulfate.
  • Stabilizing agents may include xanthan gum, locust bean gum and carrageenan, guar gum, sugars, polyols, amino acids or methylamines.
  • Emulsifying agents may include triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, veegum, sodium benzoate.
  • Permeation enhancers may include azone, alcohol, dimethyl-sulfoxide, monovalent, saturated and unsaturated aliphatic and cycloaliphatic alcohols having 6 to 12 carbon atoms such as cyclohexanol, lauryl alcohol, and the like; aliphatic and cycloaliphatic hydrocarbons such as mineral oil; cycloaliphatic and aromatic aldehydes and ketones such as cyclohexanone; N,N-di(lower alkyl)acetamides such as N,N-diethyl acetamide and N,N dimethyl acetamide, N,N-dimethyl acetamide, N-(2-hy droxyethyl)acetamide and the like; aliphatic and cycloaliphatic esters such as isopropyl myristate and lauricidin; N,N-di(lower alkyl) sulfoxides such as decylmethyl sulfoxide; essential
  • FIGS. 1, 2A, 2B , 3 and 4 Exemplary aspects of the product 1 are shown in FIGS. 1, 2A, 2B , 3 and 4 .
  • FIGS. 1, 2A and 2B show product 1 comprising a barrier patch 2 having a pressure sensitive adhesive 3 and a backing layer 4.
  • Fig. 2A is the cross section of Fig. 1 taken along 2A-2A.
  • FIG. 1 shows a plurality of soluble film zones 6 to create a series of parallel stripes offset to the longitudinal axis of the product 1.
  • the product 1 thus has alternative rows of stripes of the soluble film zones 6 applied to the upper surface 16 of the pressure sensitive adhesive 3.
  • the product 1 further comprises a soluble film zone 6 having an effective amount of a skin active agent 8.
  • the backing layer 4 further comprises a first surface 10 and a second surface 12.
  • the pressure sensitive adhesive 3 is in contact with at least part of the first surface 10 of the backing layer 4 to form a pressure sensitive adhesive coated region 14 of the first surface 10.
  • the product 1 may further comprise a cosmetic composition comprising an effective amount of a skin active agent 8.
  • the pressure sensitive adhesive 3 also comprises the cosmetic composition.
  • the cosmetic composition and skin active agent 8 is distributed to some extent and/or is homogeneously distributed throughout the soluble film zone 6.
  • the product 1 has a skin facing surface 5.
  • the skin facing surface 5 of the product 1 may comprise the upper surface 16 of the pressure sensitive adhesive, the top surface 22 of the water soluble film zone and/or the first surface 10 of the backing layer.
  • the products 1 and 40 are crescent shaped. However this shape is not intended to limit the invention.
  • Fig. 2B is an alternative cross section of the product of Fig. 1 also taken along 2A-2A.
  • Fig. 2 B shows the product 1 comprising a barrier patch 2 having a pressure sensitive adhesive 3 and a backing layer 4.
  • the product 1 further comprises a soluble film zone 6 having an effective amount of a skin active agent 8.
  • the backing layer 4 further comprises a first surface 10 and a second surface 12.
  • the pressure sensitive adhesive 3 is in contact with at least part of the first surface 10 of the backing layer 4 to form a pressure sensitive adhesive coated region 14 of the first surface 10.
  • the backing layer 4 comprises 3 layers: a non-foamed first layer 26, a foamed second layer 28 and a non-foamed third layer 30.
  • the pressure sensitive adhesive comprises an upper surface 16 and a lower surface 18.
  • the soluble film zone 6 also comprises a top surface 22 and a bottom surface 24. As shown in Fig. 2B the bottom surface 24 of the plurality of soluble film zones 6 are in contact with the upper surface 16 of the pressure sensitive adhesive 3. As shown in Figs. 1, 2A and 2B the soluble film zones 6 and the pressure sensitive adhesive 3 are substantially separate and the pressure sensitive adhesive zone 6 is continuous.
  • Figs. 3 and 4 show a product 40 comprising a barrier patch 42 having a pressure sensitive adhesive 43 and a backing layer 44.
  • Fig. 4 is the cross section of Fig. 3 taken along 4-4.
  • the product further comprises a plurality of discontinuous soluble film zones 46 having an effective amount of a skin active agent 48.
  • the backing layer 44 further comprises a first surface 50 and a second surface 52.
  • the pressure sensitive adhesive 43 is in contact with at least part of the first surface 50 of the backing layer 44 to form a plurality of pressure sensitive adhesive coated regions 54 of the first surface 50 of the backing layer 44.
  • the product 40 may further comprise a cosmetic composition comprising an effective amount of a skin active agent 48.
  • the skin active agent 48 is distributed to some extent and/or homogeneously distributed throughout each of the plurality of the soluble film zones 46.
  • the plurality of soluble film zones 46 and the adhesive zone 43 are substantially separate.
  • the soluble film zones 46 are in contact with the first surface 50 of the backing layer 44.
  • the top surface 62 of the soluble film zones and the upper surface 66 of the pressure sensitive adhesive zone 43 are co-planar or collinear.
  • the bottom surface 64 of the soluble film zone and the lower surface 68 of the pressure sensitive adhesive zone may be co-planar or collinear.
  • FIG. 5 shows a product showing an alternative pattern of discontinuous soluble film zones 70, wherein the soluble film zones 70 are configured as a series of repeating diamonds.
  • FIG. 6 shows a product showing an alternative pattern of the discontinuous soluble film zones 72 wherein the soluble film zones 72 are a series of repeating curved stripes.
  • FIG. 7 are photographs showing a multilayer beauty care product, applied to the skin, comprising a soluble film zone wherein in the left photograph the soluble film zone has a first visual state and the soluble film zone changes from the first visual state to a second visual state in the right photograph.
  • Figure 7 are photographs showing a product and/or soluble film zone having an Opacity Change Index of about 2.5 to about 50 wherein the soluble film zone or product changes from a first visual state, for example having a higher opacity in the left photograph, to a second visual state, for example having a lower opacity that is visually discernable to the user, in the right photograph.
  • the change from a first visual state to a second visual state is a result of the solubility of the polymers of the soluble film zone as determined by a change in the Opacity referred to as the Opacity Change Index.
  • the product of Fig. 7 has a backing layer of foamed EVA, Durotak 1093 adhesive available from Henkel, and a soluble film of Methocel E5LV, a cellulose either available from Dow Chemicals.
  • the backing layer is described in US Patent Serial Nos. 62/257,341 ; 62/257,347 and 62/257,351 , assignee Procter & Gamble, each filed on Nov. 19, 2015.
  • An alternative for the water soluble film forming polymer is Polyox such as Polyox WSR N750 available from Dow Chemical.
  • FIG. 8 is a photograph showing a soluble film cast on a Mylar backing.
  • Fig. 8 shows a soluble film of Polyox with a molecular weight of 200,000 cast on a Mylar backing with no glycerin present.
  • Fig. 8 is a photograph, after subjected to the Opacity Change Index Test Method herein, showing a product and/or soluble film zone wherein the soluble film zone comprises a second visual state.
  • This soluble film zone does not change from a first visual state to a second visual state when subjected to the Opacity Test and the Opacity Change Index is approximately 1.
  • the first visual state (not shown) of the sample shown in FIG. 8 is approximately the same as the second visual state.
  • Figure 9 is a photograph showing a soluble film cast on a Mylar backing wherein the soluble film comprises a second visual state.
  • Fig. 9 show a photograph of a soluble film of Polyox with a molecular weight of 200,000, having 37% glycerin, cast on a Mylar backing.
  • Fig. 9 shows a second visual state.
  • This soluble film has an Opacity Change Index of about 40.
  • the first visual state, not shown, of the sample is significantly more opaque that the second visual state.
  • Figure 10 shows the impact of including different levels of plasticizer on the dissolution of the soluble film zone in a low water environment.
  • the 200K is Polyox WSR N-80
  • the 300K is Polyox WSR N-750
  • the 900K is Polyox WSR N-1105, all available from Dow Chemical Company.
  • Figure 11 represents Franz cell penetration for data for (A) in an oil in water emulsion applied without occlusion; (B) an oil in water emulsion occluded by polyethylene terephthalate (PET) film; (C) Methocel E5LV film applied without occlusion; and (D) Methocel E5LV film occluded by PET film. Both the emulsions and the Methocel films each contained 2% inositol.
  • PET polyethylene terephthalate
  • Penetrated actives such as inositol may be quantified using Reverse Phase High Performance (or Pressure) Liquid Chromatography (RP-HPLC) with external standard quantitation at 240nm. See, for example, the Franz cell procedure in P&G's EP2561856 A1 .
  • RP-HPLC Reverse Phase High Performance Liquid Chromatography
  • the barrier patch may comprise a backing layer having a first surface and a second surface and a WVTR from about 1 g/m 2 /24 h to about 500 g/m 2 /24 h; and a pressure sensitive adhesive zone, having a upper surface and a lower surface, and the pressure sensitive adhesive may be in contact with the first surface of the backing layer.
  • the backing layer may be a co-extruded film laminate comprising at least two layers, but can comprise 3, 4, 5, 6, or more layers.
  • the backing layer or product or non-foamed first layer is substantially free of apertures.
  • apertures as used herein means films having openings of a size and shape that allow for liquid molecules to pass through the film.
  • the barrier patch of the present invention may comprise a solid sheet material.
  • the sheet provides the primary structure and shape to the product, allowing it to be handled and applied for treatment of a specific target area of the skin.
  • backing layer is generally made of a flexible film material which is capable of remaining fitted and flexing during the movement of the human body and movements especially associated with facial expressions or gestures.
  • flexible it is meant that the product, barrier patch, and/or the backing layer may be substantially bent or folded without breaking, tearing, ripping, etc.
  • the product or barrier patch also does not collapse or fold under gravity or upon handling and application by the user. It is desirable for the product to conform to the target area of the skin surface to which it is applied without folding, crinkling, or inducing more wrinkling of the target area of the skin. Accordingly, the product or barrier patch is readily conformable to the skin and remains flexible throughout the duration of use, as the user moves during the period of time worn.
  • a feature of the subject product is that the barrier patch, adhesive zone, and/or the backing layer are substantially free of, comprises only non-effective amounts of, or is free of or void of, a skin active agent.
  • the barrier patch, the adhesive zone, and/or the backing layer of the present invention may be characterized as a "blank" backing layer, adhesive zone, or barrier patch.
  • an effective amount of the skin active agent employed in the product herein is substantially separate from the barrier patch, the adhesive zone, and/or the backing layer.
  • the pressure sensitive adhesive zone and water soluble film zone are substantially separate. The term "substantially separate" as used herein means that one component is substantially free of the other component.
  • the backing layer may be a laminate comprising a film and a non-woven material for example, cotton, rayon, acrylic fibers, polypropylene fibers, polyester fibers and combinations, provided that the laminate comprises a WVTR from about 1 g/m 2 /24 h to about 500 g/m 2 /24 h.
  • the one or more layers of the barrier patch may comprise at least one material that includes but is not limited to polypropylene (PP); polyethylene (PE), metallocene plastomers, metallocene elastomers, high density polyethylene (HDPE), rubber modified LDPE, rubber modified LLDPE, acid copolymers, polysytyrene, cyclic polyolefins, polyethylene terephthalate (PET); polyvinylchloride (PVC); polyamide (PA); polycarbonate; polyurethane; cellulose acetate; polychloropene; polysulfone; polytetrafluoroethylene (PTFE); polyvinyl acetate (PVA); polyethylene glycol terephthalate film; polystyrene; polyphenylene oxide (PPO); acrylonitrile butadiene styrene (ABS); acrylic; acrylonitrile styrene acrylate (ASA); ethylene vinyl alcohol, natural rubber, latex, nylon, n
  • the backing layer(s) herein may comprise polyethylene.
  • polyethylene or "PE” is used herein the broadest sense to include PE of any of a variety of resin grades, density, branching length, copolymer, blend, catalyst, and the like.
  • the layer may comprise a blend of different grades of polyethylene, that may include LLDPE, LDPE, VLDPE, HDPE, or MDPE, or combinations thereof; manufactured using Ziegler-Natta catalysts, Chromium catalysts, metallocene based catalysts, single site catalysts, and other types of catalysts.
  • the polymers may be homopolymers or copolymers. Blends may be physical blends or reactor blends. These materials can be bio-based, petro-based and recycled/reground.
  • LLDPE copolymers can be made with any one or more of butene, hexene and octene comonomers. The ratio of the different grades can vary.
  • a preferred material for the one or more layers of the backing layer includes ethylene vinyl acetate, EVA (CAS No. 24937-78-8 ) copolymer.
  • EVA CAS No. 24937-78-8
  • Different grades of EVAs tend to have different ethylene-to-vinyl acetate monomer ratios and/or different melt indices (molecular weights).
  • the percentage of VA monomer may range from about 20% to about 50% or from about 25% to about 40% of VA or from about 25% to about 30% of VA.
  • the melt flow index may range from about 0.7 dg/min to about 60 dg/min and/or from about 2 dg/min to about 6 dg/min and/or from about 2 dg/min to about 4 dg/min.
  • EVA grades useful herein include Dupont Elvax® Grades: 260 (28% VA; Melt Flow Index MFI 6 dg/min via ASTM D1238); Grade 250 (28% VA; MFI 25 dg/min); Grade 150 and 150W (32% VA; MFI 43 dg/min); Grade 40 W (40% VA; MFI 52 dg/min); and Celanese Ateva® 2803G (28% VA; MFI 3 dg/min via ASTM D1238) and Ateva® 1807EG (18% VA; MFI 0.7 dg/min).
  • Another preferred material for the backing layer or barrier patch is a polyethylene film sold under the tradename, 1525L, available from 3M, St. Paul, Minn.
  • 3M 1525-L has a backing of polyethylene film of approximately 3 mil thickness, a 1.4 mil thick hypoallergenic, pressure sensitive acrylate adhesive layer and a paper release layer coated with polyethylene and silicone (3M 1525L may be used without the release layer).
  • a color masterbatch containing pigment and/or slip/antiblock agent and/or liquid colorants can also be added to the backing layer to afford certain aesthetics and functionality.
  • Pigments if present may typically be used in concentrations of about 0.5 wt. % to about 15 wt. %, and/or from about 1 wt. % to about 10 wt. %, or from 1.5 wt. % to about 7 wt. %, based on the total weight of the polymer (e.g. of the backing layer).
  • the backing layer of the barrier patch optionally can include an additive such as a slip agent or an antistatic agent (e.g., euracamide, a steramide), a filler (e.g., talc, clay, pulp, titanium dioxide, thermoplastic starch, raw starch wood flour, diatomaceous earth, silica, inorganic glass, inorganic salts, pulverized plasticizer, pulverized rubber), a pigment (e.g., mica, titania, carbon black), a UV inhibitor, an anti-coloring agent, a mold release agent, a flame retardant, an electrically conductive agent, an antioxidant, an impact modifier, a stabilizer (e.g., a UV absorber), wetting agents, carbon, graphene and a biodegradable-enhancing additive (e.g., an oxo-degradable additive or an organic material).
  • an additive such as a slip agent or an antistatic agent (e.g., euracamide, a steramide),
  • An oxo-degradable additive is often compounded into a polymer in a concentration of about 1 wt. % to about 5 wt. %, based on the total weight of the polymer, and includes at least one transition metal that can foster oxidation and chain scission in plastics when exposed to heat, air, light, or mixtures thereof.
  • Organic materials e.g., cellulose, starch, ethylene vinyl acetate, and polyvinyl alcohol
  • biodegradable-enhancing additives also can be used as biodegradable-enhancing additives.
  • the multi-layered co-extruded backing layer has at least three layers, and is preferably an ethylene vinyl acetate ("EVA") comprising film.
  • EVA ethylene vinyl acetate
  • a foamed layer is in-between non-foamed layers, e.g. a non-foamed first layer and a non-foamed third layer, on either side.
  • the barrier patch comprises a backing layer comprising:
  • the technique for measuring Mean Void Volume Percentage is described in US Serial Nos. 62/257,341 ; 62/257,347 and 62/257,351 .
  • the degree of foaming of a foamed layer may be characterized by a Mean Void Volume Percentage, as determined by X-ray micro-computed tomography or simply "microCT.”
  • the foamed layer comprises from 45% to 80% of a Mean Void Volume Percentage (relative to the volume of the foamed layer in total), preferably from 50% to 75%, more preferably from 55% to 73%, Mean Void Volume Percentage.
  • the backing layer of the barrier patch comprises three layers, e.g. a foamed second layer optionally comprising EVA and a layer of non-foamed EVA on either side, i.e., a first non-foamed EVA layer and a third non-foamed EVA layer wherein the foamed EVA layer is in-between said first and third non-foamed layers.
  • a foamed second layer optionally comprising EVA and a layer of non-foamed EVA on either side, i.e., a first non-foamed EVA layer and a third non-foamed EVA layer wherein the foamed EVA layer is in-between said first and third non-foamed layers.
  • the multi-layer barrier patch and/or the backing layer is substantially free of fiber, nanofibers, or non-woven material for example, cotton, rayon, acrylic fibers, polypropylene fibers, polyester fibers.
  • the barrier patch and/or backing layer includes a corona treatment.
  • the backing layer or barrier patch may be additionally treated, for example by corona discharge or coating with an adhesion promoter which as a primer may effect anchoring of the active and adhesive.
  • the material composition and/or polymer resins used in the foamed layer may be different from those used in the non-foamed layer(s), since the material composition and/or resins may be optimized for foam formation, or other film layer properties.
  • Additives, particularly small amount of nucleating agents selected from the group consisting of CaCO 3 , clays, talcs, and combinations thereof, may be included for quick bubble formation during foaming process.
  • the resin used in making the backing layer(s) of the barrier patch may include renewable materials, either "bio-identical” or “bio-new” materials, or a combination thereof.
  • bio-identical and/or bio-new materials are further detailed in U.S. patent publications from U.S. patent application serial no. 13/924983, filed June 24, 2013 (P&G US 2014/0376835 ), at pages 15-22; and U.S. patent application no. 13/924999, filed June 24, 2013 (P&G US 2014-0377512 A1 ; P&G Case 12967Q) at pages 12-20.
  • the barrier patch may include at least one layer made of a plastic resin.
  • the resin could be a traditional petro-based polyolefin, or it could be a renewable based polyolefin, or a blend thereof. Alternatively it could be a blend comprising a petro-based or renewable based polyolefin blend mixed with a renewable "bio-new" material that is chemically different to traditional petro-based polyolefins.
  • the film layer could be comprised of a material or mixture of materials having a total bio-based content of about 10% to about 100% using ASTM D6866-10, method B.
  • the layer may comprise from about 5% to about 99% by weight of a polymer (A) comprising at least one or possibly more of a low density polyethylene (LDPE), a polar copolymer of polyethylene such as ethylene vinyl acetate (EVA), a linear low density polyethylene (LLDPE), a high density polyethylene homopolymer/high density polyethylene copolymer, a medium density polyethylene, a very low density polyethylene (VLDPE), a plastomer, a polypropylene/copolypropylene/heterophasic polypropylene, polyethylene terephthalate (PET), PLA (e.g., from Natureworks), polyhydroxyalkanoate (PHA), poly(ethylene-2,5-furandicarboxylate) (PEF), cellulose (available from, for example, Innovia), NYLON 11 (i.e., Rilsan® from Arkema), starch (either thermoplastic starch or starch fillers), bio-polyes
  • polybutylene succinate polyglycolic acid (PGA), and polyvinyl chloride (PVC).
  • PGA polyglycolic acid
  • PVC polyvinyl chloride
  • At least one of the constituents of polymer (A) may be at least partially derived from a renewable resource. Recycled materials may also be in added. In specific cases, materials that are biodegradable may be utilized.
  • bio-new materials may further contribute to reflectivity of the film, as the presence of this additional material within the film layer structure can lead to additional light reflectivity, due to their typical incompatibility with the polyolefin matrix.
  • the barrier patch in order to enable better visibility of the opacity change of the water soluble film zone, is transparent, translucent, and/ or visibly clear. In one aspect the barrier patch is transparent.
  • transparent or “visibly clear” is defined as having the property of transmitting light without appreciable scattering so that bodies lying behind are perceivable.
  • transparent or “visibly clear” may also be defined as having the property of transmitting light without appreciable scattering so that bodies lying behind are perceivable and that the barrier patch or backing layer is not formed with gas bubbles entrained therein.
  • translucent may include "frosted”, “glittered”, “pearlescence” and the like and is defined herein as the practice of inducing a low level of light scattering into an otherwise “clear” material causing the material to become matted in appearance.
  • the barrier patch may comprise a backing layer and pressure sensitive adhesive zone.
  • the pressure sensitive adhesive zone comprises a pressure-sensitive adhesive (PSA) that is suitable for long-term skin contact, and which should be physically and chemically compatible with the backing layer and/or additives that are present.
  • PSA pressure-sensitive adhesive
  • suitable adhesive materials include, but are not limited to, the following: acrylic and methacrylic ester homo-or copolymers, butyl rubber based systems, silicones, urethanes, vinyl esters and amides, olefin copolymer materials, natural or synthetic rubbers, hot-melt adhesives (see, for example, U.S. Pat. No.
  • polyethylenes polysiloxanes; polyisobutylenes; polyacrylates; polyacrylamides; polyurethanes; plasticized ethylenevinyl acetate copolymers; and tacky rubbers such as polyisobutene, polybutadiene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene) and combinations thereof.
  • tacky rubbers such as polyisobutene, polybutadiene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene) and combinations thereof.
  • the adhesive is a hotmelt adhesive including adhesives selected from the group consisting of ethyl vinyl acetate, metallocene polyalphaolefins, polyolefins including atactic polyalphaolefins, block copolymers such as diblocks copolymers and triblock copolymers, polyurethane hot melts, polyamides and combinations thereof.
  • the adhesive comprises a combination of diblock copolymers and triblock copolymers.
  • Diblocks and triblock copolymers may include styrene/isoprene; styrene/butadiene; butylene / ethylene / styrene; and combinations thereof.
  • High viscosity triblock copolymers may be used as adhesives and have the configuration A-B-A wherein the polymer blocks A are non-elastomeric polymer blocks which, as homopolymers have glass transition temperatures above 20° C.
  • the elastomeric polymer blocks, B are generally isoprene or butadiene which may be partially or substantially hydrogenated or mixtures thereof. Further, the copolymers may be linear or branched.
  • Diblock copolymers may generally have the A-B configuration where A and B are as described previously.
  • Liquid diluents may be added to the adhesive compositions.
  • the adhesive composition may comprise from about 60% to about 99% diluents, by weight.
  • the majority of the liquid diluent is oil.
  • the liquid diluent comprises, or consists essentially of, oils such as highly refined white petroleum mineral oil.
  • Useful diluents are primarily aliphatic in character and compatible with the polymer midblock.
  • Plasticizers may also be included, e.g.
  • paraffinic and naphthenic petroleum oils highly refined aromatic-free paraffinic and naphthenic food and technical grade oils, highly refined white petroleum mineral oils, and liquid tackifiers such as the synthetic liquid oligomers of polybutene, polypropene, polyterpene, etc.
  • the synthetic process oils may be high viscosity oligomers which may be permanently fluid /liquid monoolefins, isoparaffins or paraffins of moderate to high molecular weight.
  • the adhesive is selected from the TECHNOMELT® and DERMA-TAK® brands available from Henkel, for example TECHNOMELT PSM 154A DERMA-TAK®.
  • DERMA-TAK products are pressure-sensitive adhesives and encompass both solvent-based acrylic and formulated rubber (liquid and hotmelt) pressure-sensitive adhesives.
  • Useful adhesives may also be selected from those described in U.S. Patent Nos. 6,448,303 and 5,559,165 .
  • the pressure sensitive adhesive zones are continuous, discontinuous, or a combination thereof.
  • the product may also comprise a plurality of discontinuous adhesive zones.
  • the overall total thickness of the barrier patch or the product is from 20 microns to 500 microns, preferably from 50 microns to 200 microns, more preferably from 70 to 180 microns, yet more preferably from 75 to 150 microns and combinations thereof.
  • the water soluble film zone (dry state) has a total thickness of about 2 microns to about 200 microns, preferably from 50 microns to about 175 microns, more preferably from about 75 to about 170 microns. In an aspect, the water soluble film zone in the dry state, has a thickness of about 5 microns to about 50 microns, or about 15 microns to about 30 microns.
  • the pressure sensitive adhesive zones typically have an average thickness ranging from about 5 microns to about 350 microns, in alternative aspects about 10 microns to about 120 microns.
  • the typical basis weight for the product herein ranges from about 40 to about 190 gsm, for instance about 45 gsm to about 170 gsm and/or from about 50 gsm to about 140 gsm.
  • the pressure sensitive adhesive zone and the water soluble film zone may be continuous or discontinuous such that they comprise continuous or discontinuous patterns.
  • the adhesive zone and the soluble film zone may both be continuous.
  • a portion of the adhesive zone and the soluble film zone are continuous and another portion may be discontinuous.
  • the soluble film zone should be applied to the adhesive zone so that it covers about 1% to about 99% of the skin facing surface area of the adhesive zone or product, or about 10% to about 90%, and/or about 20% to about 80% of the skin facing surface area of the adhesive zone or the product.
  • the pressure sensitive adhesive zone is applied to the backing layer in a pattern to define a pattern of discontinuous adhesive free areas and the soluble film zone is applied to the adhesive free areas of the backing layer.
  • the pressure sensitive adhesive zone is applied to the backing layer in a series of rows or stripes to define a pattern of adjacent adhesive free areas that are stripes or rows, and the soluble film zone is applied to the adhesive free areas/stripes of the backing layer.
  • the pressure sensitive adhesive zone is applied to the backing layer as a continuous layer and the soluble film zone is applied, as a discontinuous pattern, to the upper surface of the adhesive zone.
  • the soluble film zone may be applied to the adhesive zone or the backing layer in a regular pattern, a random pattern, and combinations thereof.
  • the soluble film zone may be configured in either a regular or random pattern of elements such as straight lines, angled lines, curved lines, intersecting lines, dots, circles and geometric shapes, amorphous shaped, etc. or a combination of these elements.
  • the product may have a size and shape adapted to conform to a desired target area of skin which could be a human face or part thereof, legs, hands, arms, feet, or human torso. They are generally flat in appearance.
  • the exact size and shape of the product will depend upon the intended use and product characteristics.
  • the product herein can be, for example, a square, circle, semicircle, rectangle, triangle, oval, ring, crescent, crescent with rounded corners, teardrop or other more complex and irregular shape.
  • the shape of the barrier patch may be selected from the group consisting of circle, square, rectangle, triangle, and/or irregular shape that conforms to the contours of the forehead, perioral, and/or periorbital areas of the human face.
  • the product comprises a size and shape to treat different areas of the face such as the forehead, the under eye area and the under eye area combined with the crows feet area around the eye.
  • the size of the product may be determined by the size of the target area of skin to be treated.
  • the surface area may range from about 0.25 cm 2 to about 50 cm 2 , and/or from about 1 cm 2 to about 30 cm 2 , and/or from about 1 cm 2 to about 20 cm 2 , and/or from about 1 cm 2 to about 15 cm 2 , and/or from about 5 cm2 to about 15 cm 2 .
  • Surface area refers to that of a flat plane having the same boundary as the surface i.e. ignoring any surface texturing present.
  • the backing layer or barrier patch has an WTVR value between about 1 g/m 2 /24 h to about 500 g/m 2 /24 h, and in another aspect has a WVTR from about 1 g/m 2 /24 h to about 250 g/m 2 /24 h and/or from about 1 g/m 2 /24 h to about 180 g/m 2 /24 h and/or from about 2 g/m 2 /24 h to about 150 g/m 2 /24 h and/or from about 2 to about 20 g/m 2 /24 h.
  • WTVR stands for "Water Vapor Transmission Rate", i.e. the amount of vapor which can pass per unit area during a certain period of time.
  • the backing layer or barrier patch in certain aspects is non-porous or water impermeable.
  • the multi-layered barrier patch or backing layer is impermeable to the cosmetic composition, the soluble film zone, the skin care active agent employed, and fluids wherein the WVTR is from about from about 2 to about 100 g/m 2 /24 h.
  • a backing layer or barrier patch that minimizes water loss from the soluble film or cosmetic composition while in contact with the keratinous tissue and skin, prevents the water soluble film zone or cosmetic composition, once hydrated, from drying out. This drying out may result in reduced or loss of efficacy and/or irritation to the skin.
  • Such relative water impermeability and lower water vapor permeability of the barrier patch may increase the effectiveness and efficiency of the cosmetic composition.
  • the relative water impermeability and lower vapor permeability of the barrier patch employed may serve to enhance or increase the penetration of the skin care active agent into the skin.
  • the backing layer or barrier patch may, for example, consist of a perforated polyolefin film, where the size of the holes has been chosen so that air and vapor may pass, but not liquid molecules.
  • a perforated polyolefin film is described in U.S. Pat. No. 5,628,737 and/or microporous plastic films, as is described in, for example, EP-A-0238200 . These laminates and films, however, are not preferred herein due to their relatively high WVTR and higher levels of breathability.
  • the product herein may further optionally comprise a protective release layer removably attached to the consumer facing side of the pressure sensitive adhesive or the soluble film zone of the product.
  • the release layer provides protection for the pressure sensitive adhesive zone and/or the soluble film zone from the environment and prior to application by the user.
  • the protective release layer may comprise materials including polymer resins such as a polyolefins e.g. polypropylene (including stratified biaxially oriented polypropylene (SBOPP)), polyethylene (including LDPE; LLDPE; HDPE; Metallocene) or polyethylene terephthalate, polyesters, and combinations thereof.
  • polymer resins such as a polyolefins e.g. polypropylene (including stratified biaxially oriented polypropylene (SBOPP)), polyethylene (including LDPE; LLDPE; HDPE; Metallocene) or polyethylene terephthalate, polyesters, and combinations thereof.
  • the protective release layer may comprise one or more laminations, combinations of multiple layers.
  • the protective release layer may comprise a coating of a non-stick material.
  • non-stick coatings include wax, silicone, fluoropolymers such as TEFLON®, and fluorosilicones.
  • the protective release layer covers the entire aforementioned area of pressure sensitive adhesive zone coating the barrier patch.
  • the protective release layer is water impermeable.
  • the release layer has a mean thickness of at least about 50 microns, or at least about 85 microns, or from about 50 microns to about 150 microns, and/or from about 90 microns to about 120 microns.
  • the release layer may optionally extend, in whole or part, beyond the pressure sensitive adhesive zone to provide a removal tab that facilitates ease of removal of the release layer.
  • the water soluble film zone comprises a cosmetic composition comprising an effective amount of a skin active agent and a water soluble film forming polymer.
  • the composition may also comprise a dermatologically acceptable carrier.
  • the product provides an effective amount of a skin active agent to be delivered to the target area of skin.
  • the product provides from about 0.5 mg/cm2 to about 3 mg/cm2 of the cosmetic composition, and/or from about 1 mg/cm2 to about 2 mg/cm2 to the target area of skin.
  • the use of the proper amount of the cosmetic composition will minimize the interaction of the cosmetic composition with the pressure sensitive adhesive.
  • the compositions of the present invention may comprise a skin active agent which provides a particular skin care benefit characteristic of the usage of the skin care product.
  • the skin care benefit may include benefits related to appearance or make-up of the skin.
  • the skin care active can provide acute (immediate and short lived) benefits, or chronic (long term and longer lasting) benefits.
  • skin active agent means an active ingredient which provides a cosmetic and/or therapeutic effect to the area of application on the skin.
  • the skin active agents useful herein include skin lightening agents, anti-acne agents, emollients, non-steroidal antiinflammatory agents, topical anesthetics, artificial tanning agents, anti-microbial and anti-fungal actives, skin soothing agents, sun screening agents, skin barrier repair agents, anti-wrinkle agents, anti-skin atrophy actives, lipids, sebum inhibitors, sebum inhibitors, skin sensates, protease inhibitors, anti-itch agents, desquamation enzyme enhancers, anti-glycation agents, diaper rash agents, anti-eczema agents, botanicals, and mixtures thereof.
  • the present composition comprises a safe and effective amount of a skin active agent and/or from about 0.0001% to about 20%, in another aspect from about 0.01% to about 10% of at least one skin active agent.
  • the cosmetic compositions may include from about 0.00001 to about 10 % by weight of botanical actives or from about 0.01 to about 8 percent by weight, or from about 0.05 to about 5 percent by weight.
  • Botanical herein means a substance, extract or derivative of a plant and may also be described as “herbals”.
  • Botanicals may include water-soluble or oil-soluble active materials extracted from a particular plant including materials extracted from echinacea, yucca glauca, willow herb, basil leaves, Vietnamese oregano, carrot root, grapefruit fruit, fennel fruit, rosemary, thyme, blueberry, bell pepper, black tea, blackberry, black currant fruit, Chinese tea, coffee seed, dandelion root, date palm fruit, gingko leaf, green tea polyphenols (e.g.
  • epicatechin gallate and epigallocatechin 3-O-gallate hawthorn berries, licorice, oolong tea, sage, strawberry, sweet pea, tomato, vanilla fruit, neohesperidin, quercetin, rutin, morin, myricetin, chlorogenic acid, glutathione, glycyrrhizin, absinthe, arnica, centella asiatica, chamomelle, comfrey, cornflower, horse chestnut, ivy (Herdera helix), magnolia, mimosa, oat extract, pansey, scullcap, seabuckthorn, white nettle, witch hazel and any combinations thereof.
  • the type and amount of skin active agents are selected so that the inclusion of a specific agent does not affect the stability of the composition.
  • hydrophilic agents may be incorporated in an amount soluble in the aqueous phase
  • lipophilic agents may be incorporated in an amount soluble in the oil phase.
  • Other skin active agents purported to exhibit expression-line relaxing benefits for use in the present invention include, but are not limited to, Lavandox available from Barnet Products Corporation; Thallasine 2, available from BiotechMarine; Argireline NP, available from Lipotec; Gatuline In-Tense and Gatuline Expression, available from Gattefosse; Myoxinol LS 9736 from BASF Chemical Company, Syn-ake, available from DSM Nutritional Products, Inc.; and Instensyl®, available from Silab, Inc; SesaflashTM, available from Seppic Inc.
  • Skin lightening agents useful herein refer to active ingredients that improve hyperpigmentation as compared to pre-treatment.
  • Useful skin lightening agents herein include ascorbic acid compounds, vitamin B3 compounds, azelaic acid, butyl hydroxyanisole, gallic acid and its derivatives, glycyrrhizinic acid, hydroquinone, kojic acid, arbutin, mulberry extract, and mixtures thereof.
  • Use of combinations of skin lightening agents is believed to be advantageous in that they may provide skin lightening benefit through different mechanisms.
  • Ascorbic acid compounds useful herein include ascorbic acid per se in the L-form, ascorbic acid salt, and derivatives thereof.
  • Ascorbic acid salts useful herein include, sodium, potassium, lithium, calcium, magnesium, barium, ammonium and protamine salts.
  • Ascorbic acid derivatives useful herein include, for example, esters of ascorbic acid, and ester salts of ascorbic acid.
  • Particularly preferred ascorbic acid compounds include 2-o-D-glucopyranosyl-L-ascorbic acid, which is an ester of ascorbic acid and glucose and usually referred to as L-ascorbic acid 2-glucoside or ascorbyl glucoside, and its metal salts, and L-ascorbic acid phosphate ester salts such as sodium ascorbyl phosphate, potassium ascorbyl phosphate, magnesium ascorbyl phosphate, and calcium ascorbyl phosphate.
  • 2-o-D-glucopyranosyl-L-ascorbic acid which is an ester of ascorbic acid and glucose and usually referred to as L-ascorbic acid 2-glucoside or ascorbyl glucoside, and its metal salts
  • L-ascorbic acid phosphate ester salts such as sodium ascorbyl phosphate, potassium ascorbyl phosphate, magnesium ascorbyl phosphate, and calcium ascorbyl phosphate.
  • ascorbic compounds include magnesium ascorbyl phosphate available from Showa Denko, 2-o-D-glucopyranosyl-L-ascorbic acid available from Hayashibara and sodium L-ascorbyl phosphate with tradename STAY C available from Roche.
  • Vitamin B 3 compounds useful herein include, for example, those having the formula: wherein R is -CONH2 (e.g., niacinamide) or -CH2OH (e.g., nicotinyl alcohol); derivatives thereof; and salts thereof.
  • exemplary derivatives of the foregoing vitamin B 3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • Preferred vitamin B 3 compounds are niacinamide and tocopherol nicotinate, and in another aspect is niacinamide.
  • the vitamin B 3 compound contains a limited amount of the salt form and is more preferably substantially free of salts of a vitamin B3 compound.
  • the vitamin B 3 compound contains less than about 50% of such salt, and is more preferably substantially free of the salt form.
  • Commercially available vitamin B 3 compounds that are highly useful herein include niacinamide USP available from Reilly.
  • hydrophobic skin lightening agents useful herein include ascorbic acid derivatives such as ascorbyl tetraisopalmitate (for example, VC-IP available from Nikko Chemical), ascorbyl palmitate (for example available from Roche Vitamins), ascorbyl dipalmitate (for example, NIKKOL CP available from Nikko Chemical); undecylenoyl phenyl alanine (for example, SEPIWHITE MSH available from Seppic); octadecenedioic acid (for example, ARLATONE DIOIC DCA available from Uniquema); oenothera biennis sead extract, and pyrus malus (apple) fruit extract, Water and Myritol 318 and butylene glycol and tocopherol and sscorbil tetraisopalmitate and Paraben and Carbopol 980 and DNA / SMARTVECTOR UV available from COLETICA, magnesium ascorbyl phosphate in hyaluronic filling
  • skin active agents useful herein include those selected from the group consisting of N-acetyl D-glucosamine, panthenol (e.g., DL panthenol available from Alps Pharmaceutical Inc.), tocopheryl nicotinate, benzoyl peroxide, 3-hydroxy benzoic acid, flavonoids (e.g., flavanone, chalcone), farnesol, phytantriol, glycolic acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, retinyl esters (e.g., retinyl propionate), phytic acid, N-acetyl-L-cysteine, lipoic acid, tocopherol and its esters (e.g., tocopheryl acetate: DL- ⁇ -
  • compositions of the present invention in various aspects may comprise N-acyl amino acid compounds.
  • Suitable N-acyl amino acid compounds include, but are not limited to, N-acyl phenylalanine, N-acyl tyrosine, their isomers, including their D and L isomers, salts, derivatives, and mixtures thereof.
  • An example of a suitable N-acyl amino acid is N-undecylenoyl-L-phenylalanine is commercially available under the tradename SEPIWHITE (Registered trademark) from Seppic (France).
  • the cosmetic composition may comprise one or more peptides.
  • peptide refers to peptides containing ten or fewer amino acids, their derivatives, isomers, and complexes with other species such as metal ions (for example, copper, zinc, manganese, and magnesium).
  • metal ions for example, copper, zinc, manganese, and magnesium.
  • peptide also refers to both naturally occurring and synthesized peptides.
  • the peptides are di-, tri-, tetra-, penta-, and hexa-peptides, their salts, isomers, derivatives, and mixtures thereof.
  • peptide derivatives include, but are not limited to, peptides derived from soy proteins, palmitoyl-lysine-threonine (pal-KT) and palmitoyl-lysine-threonine-threonine-lysine-serine (pal-KTTKS, available in a composition known as MATRIXYL®) palmitoyl-glycine-glutamine-proline-arginine (pal-GQPR, available in a composition known as RIGIN®), these three being available from Sederma, France, and Cu-histidine-glycine-glycine (Cu-HGG, also known as IAMIN®).
  • the cosmetic composition may comprise from about 1 x 10 -7 % to about 20%, alternatively from about 1 x 10 -6 % to about 10%, and alternatively from about 1 x 10 -5 % to about 5% of the peptide.
  • the skin active agent is niacinamide.
  • the agent is a combination of niacinamide, glycerine, tocopherol acetate, and D-panthenol.
  • Niacinamide may be included in the composition in an amount between about 1% to about 30 wt%, in another aspect from about 2% to about 28 wt%, in another aspect from about 5% to about 25 wt%, and in another aspect from about 10% to about 20 wt%.
  • D-panthenol When D-panthenol is included, it may be present in an amount of about 0.5% to about 5 wt%, or about 0.5% to about 3 wt% and/or about 0.5% to about 2 wt%.
  • Glycerin may be included as an active in an amount from about 6% to about 20 wt%, and/or from about 8% to about 15 wt%, and/or from about 10% to about 15 wt%.
  • the skin active agent is selected from niacinamide, alone or in combination with one or more of palmitoyl-lysine-threonine, palmitoyl-lysine-threonine-threonine-lysine-serine, N-undecyl-10-enoyl-L-phenylalanine, retinyl propionate, N-acetyl glucosamine, vitamin C, tretinoin, salicylic acid, benzoic acid, benzoyl peroxide, tretinoin, and combinations thereof.
  • the cosmetic compositions herein may be aqueous solutions, or emulsions such as oil-in-water emulsions, water-in-oil emulsions or multiple emulsions having aqueous or oily external phases.
  • the cosmetic compositions herein are oil-in-water emulsions.
  • the cosmetic composition or water soluble film zone comprises only low levels of silicones of about 0.5% to about 10%, and/or from about 1% to about 5% and/or the cosmetic composition is substantially free of silicones.
  • silicones may refer to those silicones disclosed in US 2007/0020220A1, published Jan. 25, 2007 , Osborne, for example in paragraphs [0226] to [0258].
  • the cosmetic composition is substantially free of depilatory agents.
  • the cosmetic composition or water soluble film zone may comprise an effective amount of a skin active agent having activity to improve visual or aesthetic appearance of the skin, such as an agent effective to reduce or diminish the appearance of fine lines and/or wrinkles on human facial skin or an agent effective to treating existing acne lesions, reducing redness associated with acne lesions and/or protecting from formation of acne lesions.
  • a skin active agent having activity to improve visual or aesthetic appearance of the skin, such as an agent effective to reduce or diminish the appearance of fine lines and/or wrinkles on human facial skin or an agent effective to treating existing acne lesions, reducing redness associated with acne lesions and/or protecting from formation of acne lesions.
  • a method of treating skin comprising applying the product to a target area of the skin, comprising an effective amount of a skin active agent.
  • the methods of treatment, application, regulation, or improvement disclosed herein may utilize the aforementioned product and/or multi-layered barrier patch.
  • Application of the present product can occur on any target area of skin surface of the body. Skin surfaces of the most concern tend to be those not typically covered by clothing such as facial skin surfaces, hand and arm skin surfaces, foot and leg skin surfaces, and neck and chest skin surfaces (e.g., Vietnameselletage).
  • application may be on a facial skin surface including the forehead, perioral, chin, periorbital, nose, and/or cheek skin surfaces.
  • the step of applying the product to a target area of skin may be done by localized application to the target area, for example an area that contains wrinkles.
  • the term "localized”, “local”, or “locally” mean that it is delivered to the target area of skin (such as an area of skin containing wrinkles) while minimizing delivery to skin surface not requiring treatment.
  • One or more products of the present invention can be applied broadly to one or more facial skin surfaces to reduce the appearance of wrinkles within those facial skin regions.
  • the method of treating skin herein may optionally begin with a cleansing step.
  • the consumer can wash his or her face with a suitable cleanser (e.g., Olay Purifying Mud Lathering Cleanser, available from The Procter & Gamble Company, Cincinnati, OH), and gently dry his or her skin.
  • a suitable cleanser e.g., Olay Purifying Mud Lathering Cleanser, available from The Procter & Gamble Company, Cincinnati, OH
  • the product may be applied to at least one target portion of skin selected from the group consisting of a forehead, perioral, chin, periorbital, nose, cheek, skin surface, and combinations thereof.
  • the product may be applied to the target portion of skin for a treatment period.
  • the treatment period may comprise at least once a day for at least four weeks, preferably applied at least twice a day for at least four weeks, more preferably at least once a day for at least eight weeks, and more preferably at least twice a day for at least eight weeks, preferably the length of the treatment period is at least 2 weeks, preferably at least 4 weeks, and more preferably at least 8 weeks.
  • the product may remain on the target portion of skin for about 1 minute to about 24 hours or from about 2 hours to about 10 hours, prior to the removal from the skin.
  • the target portion of skin comprises a hyperpigmented spot, wrinkles, fine lines, dryness, skin laxity and combinations thereof.
  • the opacity is the measure of the capacity of a material to obscure what is in the background.
  • the Opacity Change Index as used herein measures the change in opacity when the product or water soluble film zone or soluble film sample (made from the water soluble film forming polymer), is subject to the solubility test method herein.
  • the Opacity Change Index of the soluble film or product herein is from about 2.5 to about 50, or from about 3 to about 40 or from about 5 to about 20.
  • WVTR of the barrier patch or backing layer is measured according to ASTM F1249 13 at 37°C and 35% RH. Samples may be analyzed on a MOCON Permatran-W 3/33 Water Vapor Permeability Instrument using ASTM F1249. For samples with higher WVTR (e.g. from approximately 300 g/m 2 /24 h to 500 g/m 2 /24 h) samples may be analyzed per ASTM E-96 with desiccant placed inside the test cups and 35% RH surrounding the exterior of the cups. Samples of barrier patches are prepared and do not include the pressure sensitive adhesive.
  • Thickness measurement may be performed using ASTM D5729 which typically uses a pad caliper with a known pressure (0.1psi) and a gage sensor.
  • a Qualitest Thickness Tester, Model CHY-C2, available from www.WorldofTest.com may be used.
  • the water soluble film is aged for 24 hours at 21° C (+/-1.5° C) and 50% relative humidity (+1-1.5% relative humidity). Cut three test specimens of the water-soluble film sample to a size of 3.8 cm x 3.2 cm. Lock each specimen in a separate 35 mm slide mount. Fill a suitable beaker with 500 mL of distilled water, and maintain a constant temperature of 20° C. Mark height of column of water. Place beaker on magnetic stirrer, add magnetic stirring rod to beaker, turn on stirrer, and adjust stir speed until a vortex develops which is approximately one-fifth the height of the water column. Mark depth of vortex.
  • Solution A Mix the ingredients of Solution A and heat to 80°C with stirring. Then place Solution B ingredients into a small beaker and stir until the solution becomes clear to deprotonate the Sepiwhite MSH to make it soluble in water. Then heat ingredients of Solution C to 80°C with stirring.
  • An alternative polymer solution may be used and is prepared as follows. Place 535.8g of ethanol in a beaker and stir with an overhead mixer at 300RPMs. Then add 0.2g of phenoxyethanol stir. Once dispersed, add 200g of 200k PEO (Polyox WSR N-80, with a molecular weight of about 200,000 available 1 Available from BASF. 2 Available from BASF. 3 Available from BASF. from Dow) and stir at 300RPMs for 15 minutes to disperse. Once dispersed, add 264g of distilled water and stir at 100RPMs for 2 hours. Then mix the polymer solution with the emulsion at a 60:40 ratio mixture of polymer solution to emulsion. Then cast a film with the use of a Gardo Draw Down table and a #44 Draw Down bar, onto a transfer sheet.
  • 200k PEO Polyox WSR N-80, with a molecular weight of about 200,000 available 1 Available from BASF. 2 Available from BASF. 3
  • An alternative polymer solution may be used and is prepared as follows. Place 799.8g of distilled water in a beaker and heat to 95C with stirring from an overhead mixer at 300RPMs. Once at 95C, add 0.2g of phenoxyethanol and stir until dispersed. Next, add Methocel E5LV powder with stirring at 300RPMs. Once all the Methocel E5LV is added, remove heat and stir the mixture at 300RPMs until at 60C. Once at 60C, turn down the stirring to 150RPMs and place the beaker in an ice bath and stir until completely hydrated, usually overnight. Then mix the polymer solution with the emulsion at a 60:40 ratio mixture of polymer solution to emulsion.
  • the polymer solutions may be prepared with solvents selected from the group consisting of water, ethanol, isopropanol, propanol, and other water soluble solvents such as alcohols, glycols, and combinations thereof.
  • Sample 3 is a 3 layer film having a foamed core layer and non-foamed outer layers. All layers are made of EVA. The outside layers each have approximately 20 ⁇ m thickness and the core foamed layer has approximately 130 ⁇ m thickness. The total thickness of the backing layer is approximately 170 ⁇ m. The basis weight is about 99 gsm and the WVTR is 82 g/m 2 /24 hours.
  • the backing layer has a first surface.
  • the backing layer may comprise a low density polyethylene film or a non-foamed laminate of EVA.
  • the backing layer or barrier patch may also comprise a polyethylene film sold under the tradename, 3M 1525L, available from 3M, St. Paul, Minn, (without the release layer) which has a backing of polyethylene film of approximately 3 mil thickness and a 1.4 mil thick hypoallergenic, pressure sensitive acrylate adhesive layer.
  • a pressure sensitive adhesive (if an adhesive is not already present with the backing layer), such as for example, TECHNOMELT® and DERMA-TAK® brands available from Henkel, (for example TECHNOMELT PSM 154A DERMA-TAK®) at a basis weight of about 50 g/m 2 to about 160 g/m 2 or specifically about 95 g/m 2 , on the first surface of the backing layer.
  • Slot coat the pressure sensitive adhesive as a continuous layer across the first surface of the backing layer.
  • the upper surface of the pressure sensitive adhesive layer/zone is coated with the above soluble film comprising the skin active agent by contacting the soluble film side of the transfer sheet to the upper surface of pressure sensitive adhesive.
  • the soluble film is coated as a discontinuous layer on the upper (outer) surface of the pressure sensitive adhesive layer/zone.
  • the soluble film has a coating basis weight from about 30 g/ m 2 to about 200 g/ m 2 .
  • the assembly of the barrier patch may also be accomplished by the methods described in US Serial Nos. 62/257,341 ; 62/257,347 and 62/257,351 , assignee Procter & Gamble, each filed on Nov. 19, 2015.
  • Exemplary products for example the Product of the above example, for treatment of periorbital skin aging are attached, via the adhesive side, to periorbital area.
  • the Product is applied and worn for an extended period of time of approximately 7-8 hours such as overnight, and thereafter removed.
  • the Products herein deliver an effective amount of the skin active agent in a manner that achieves penetration of the skin active agent into the stratum corneum, and/or other layers of the epidermis, and in many aspects, into the basal skin layer and/or dermis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Claims (12)

  1. Produit de soins esthétiques multicouche pour application d'un agent actif pour la peau sur la peau, comprenant :
    une zone de film hydrosoluble comprenant :
    un polymère filmogène hydrosoluble comprenant un polymère choisi dans le groupe constitué d'oxyde de polyéthylène et de combinaisons de celui-ci ; et
    une composition cosmétique comprenant une quantité efficace d'un agent actif sur la peau ;
    une pastille barrière comprenant :
    une couche de support ayant une première surface et une deuxième surface ; et
    une zone d'adhésif sensible à la pression, ayant une surface supérieure et une surface inférieure, la surface inférieure de l'adhésif sensible à la pression en contact avec la première surface de la couche de support ;
    et dans lequel l'adhésif sensible à la pression est de préférence choisi dans le groupe constitué d'homo- ou copolymères d'ester acrylique et méthacrylique, des systèmes à base de caoutchouc butyle, de silicones, d'uréthanes, d'esters et amides vinyliques, de matériaux copolymères d'oléfine, et de combinaisons de ceux-ci ;
    dans lequel la zone de film soluble est en contact avec soit la première surface de la couche de support, soit la surface supérieure de la zone adhésive, soit l'une et l'autre, et la zone de film soluble ou le produit est susceptible de passer d'un premier état visuel à un deuxième état visuel, comprenant de préférence un indice de changement d'opacité de 2,5 à 50, plus préférablement de 3 à 40, selon le procédé de test d'opacité, décrit ici.
  2. Produit selon la revendication 1 dans lequel la couche de support comprend un taux de transmission de vapeur d'eau allant de 1 g/m2/24 h à 500 g/m2/24 h.
  3. Produit selon une quelconque revendication précédente dans lequel le polymère filmogène hydrosoluble est choisi dans le groupe constitué d'oxyde de polyéthylène ayant une masse moléculaire allant de 500 à 10 000 000, de préférence de 10 000 à 1 000 000.
  4. Produit selon une quelconque revendication précédente dans lequel la zone adhésive, la couche de support, ou la pastille barrière est essentiellement dépourvue d'une quantité efficace d'un agent actif sur la peau.
  5. Produit selon une quelconque revendication précédente dans lequel la zone de film hydrosoluble comprend en outre de 2 % à 80 % en poids de la zone de film soluble, d'un plastifiant dans lequel de préférence le plastifiant est choisi dans le groupe constitué de glycérol, éthylène glycol, diéthylène glycol, propylène glycol, sorbitol, pentaérythritol, glucamine, N-méthylglucamine, cumènesulfonate de sodium, et des combinaisons de ceux-ci.
  6. Produit selon une quelconque revendication précédente dans lequel la zone de film hydrosoluble et la zone adhésive sont essentiellement indépendantes.
  7. Produit selon une quelconque revendication précédente dans lequel le produit comprend une pluralité de zones de film hydrosoluble discontinues.
  8. Produit selon une quelconque revendication précédente dans lequel la zone de film hydrosoluble comprend en outre une surface de dessus et une surface de fond dans lequel la surface de fond de la zone de film soluble est en contact avec la surface supérieure de la zone adhésive et la zone adhésive est continue ou dans lequel la surface de dessus de la zone de film soluble et la surface supérieure de la zone adhésive sont coplanaires ou colinéaires.
  9. Produit selon une quelconque revendication précédente dans lequel la zone de film hydrosoluble a une épaisseur totale de 2 micromètres à 200 micromètres, et de préférence la pastille barrière ou le produit a une épaisseur totale de 20 micromètres à 500 micromètres.
  10. Produit selon une quelconque revendication précédente dans lequel le produit, la pastille barrière, ou la couche de support est essentiellement dépourvu de matériaux fibreux absorbants, de matériaux superabsorbants, de matériaux non-tissés, de coton, de rayonne, d'acryliques, de fibres de polypropylène et de fibres de polyester.
  11. Produit selon une quelconque revendication précédente dans lequel la pastille barrière ou la couche de support est transparente.
  12. Produit selon une quelconque revendication précédente dans lequel la zone de film hydrosoluble comprend en outre une émulsion huile dans eau ou eau dans huile et a une opacité initiale mesurée de la façon décrite ici allant d'environ 10 à environ 100 et de préférence le polymère filmogène hydrosoluble est utilisé à un taux qui est en excès de l'émulsion, en poids de la zone de film hydrosoluble moyennant quoi de préférence la zone de film hydrosoluble peut comprendre d'environ 35 % à 45 % de l'émulsion et d'environ 51 % à environ 70 % du polymère filmogène hydrosoluble.
EP18709138.4A 2017-01-09 2018-01-09 Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau Active EP3565641B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444042P 2017-01-09 2017-01-09
PCT/US2018/012871 WO2018129495A1 (fr) 2017-01-09 2018-01-09 Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau

Publications (2)

Publication Number Publication Date
EP3565641A1 EP3565641A1 (fr) 2019-11-13
EP3565641B1 true EP3565641B1 (fr) 2021-06-23

Family

ID=61569362

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18709139.2A Withdrawn EP3565642A1 (fr) 2017-01-09 2018-01-09 Timbre barrière comportant un film soluble et procédés pour améliorer l'aspect de la peau
EP18709138.4A Active EP3565641B1 (fr) 2017-01-09 2018-01-09 Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18709139.2A Withdrawn EP3565642A1 (fr) 2017-01-09 2018-01-09 Timbre barrière comportant un film soluble et procédés pour améliorer l'aspect de la peau

Country Status (5)

Country Link
US (2) US10799431B2 (fr)
EP (2) EP3565642A1 (fr)
JP (1) JP6974922B2 (fr)
CN (2) CN110167642B (fr)
WO (2) WO2018129496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6513800B2 (ja) 2014-10-21 2019-05-15 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するためのキット
WO2017070078A1 (fr) 2015-10-22 2017-04-27 The Procter & Gamble Company Timbre barrière d'un film expansé et procédés d'amélioration de l'aspect de la peau
EP3364936B1 (fr) 2015-10-22 2019-11-20 The Procter and Gamble Company Timbre barrière d'un film expansé et procédés pour améliorer l'aspect de la peau
WO2018129496A1 (fr) 2017-01-09 2018-07-12 The Procter & Gamble Company Timbre barrière comportant un film soluble et procédés pour améliorer l'aspect de la peau
US10751265B2 (en) 2017-01-09 2020-08-25 The Procter & Gamble Barrier patch with soluble film and methods of improving skin appearance
US10857076B2 (en) 2017-01-09 2020-12-08 The Procter & Gamble Company Barrier patch with soluble film and methods of improving skin appearance
CN110769945B (zh) 2017-06-22 2023-01-24 宝洁公司 包括水溶性层和气相沉积涂层的美容护理品膜
US10751266B2 (en) 2018-03-19 2020-08-25 The Procter & Gamble Company Method of making a barrier patch with soluble film
CN112384307B (zh) * 2018-06-29 2023-06-16 宝洁公司 双相产品分配器
US20210130752A1 (en) * 2019-11-05 2021-05-06 The Procter & Gamble Company Substrates having water-soluble polymer zones comprising a freshening active and consumer products comprising the same
CN115607725A (zh) * 2021-12-31 2023-01-17 上海炫鑫医药科技有限公司 一种强抗菌性的医用敷料及其制备方法

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155034A (en) 1961-11-01 1964-11-03 Rineglas Inc Silk screen printing press
US3482300A (en) 1966-10-31 1969-12-09 Screen Printing Systems Inc Printing screen and method of making same
US3696741A (en) 1969-12-03 1972-10-10 George W Reinke Foraminous printing screen
US3759799A (en) 1971-08-10 1973-09-18 Screen Printing Systems Method of making a metal printing screen
US3759800A (en) 1971-09-27 1973-09-18 Screen Printing Systems Seamless rotary printing screen and method of making same
JPS5052044U (fr) 1973-09-08 1975-05-20
US4341209A (en) 1981-01-12 1982-07-27 The Kendall Company Adhesive bandage with foam backing
EP0066672B1 (fr) 1981-06-09 1987-09-02 Mitsubishi Kasei Corporation Procédé de fabrication de feuilles ou films poreux
US4377616A (en) 1981-12-30 1983-03-22 Mobil Oil Corporation Lustrous satin appearing, opaque film compositions and method of preparing same
JPS6033021U (ja) 1983-08-12 1985-03-06 大道　七海男 パツケ−ジ
DE3423328A1 (de) 1984-06-23 1986-01-02 Beiersdorf Ag, 2000 Hamburg Selbstklebendes pflaster
DE3423293C2 (de) 1984-06-23 1995-08-24 Lohmann Therapie Syst Lts Selbstklebendes Pflaster
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4773408A (en) 1985-01-04 1988-09-27 E. R. Squibb & Sons, Inc. Wound dressing
US4649186A (en) 1985-07-01 1987-03-10 Eastman Kodak Company Process for preparing copolymers of ethylene and vinyl acetate
US4578297A (en) 1985-07-11 1986-03-25 Mobil Oil Corporation Polymer film/polymer foam laminate and heat-resistant container fabricated therefrom
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
GB8604117D0 (en) 1986-02-19 1986-03-26 Mclauchlan R A Light tube protector
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4781294A (en) 1986-10-08 1988-11-01 Warner-Lambert Company Tear oriented package
DK157899C (da) 1987-12-15 1990-09-03 Coloplast As Hudpladeprodukt
GB8818114D0 (en) 1988-07-29 1988-09-01 Johnson & Johnson Haemostatic wound dressing material
WO1990013420A1 (fr) 1989-05-11 1990-11-15 Landec Labs, Inc. Ensembles adhesifs actives par la temperature
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
JPH0645227B2 (ja) 1989-09-25 1994-06-15 チッソ株式会社 不透明で真珠様光沢を有する積層延伸成形物及びその製造方法
US5455043A (en) 1990-06-13 1995-10-03 Fischel-Ghodsian; Fariba Device for controlled release of vaporous medications through nasal route
GB9105977D0 (en) 1991-03-21 1991-05-08 Smith & Nephew Percutaneous anaesthesia
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
DE69229122T2 (de) 1991-11-06 2000-01-05 Bioderm Inc 0kklusiver wundverband sowie vorrichtung zum anbringen
JPH0679002A (ja) 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc 経皮投与用パッチシステム
ES2099974T3 (es) 1992-09-25 1997-06-01 Minnesota Mining & Mfg Tratamiento de la piel con propiedades de mejora de la adherencia.
DE4308649C2 (de) 1993-03-18 1995-11-16 Lohmann Gmbh & Co Kg Medizinisches Pflastermaterial sowie Verfahren zu seiner Herstellung und dessen Verwendung
US5503844A (en) 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
US5670557A (en) * 1994-01-28 1997-09-23 Minnesota Mining And Manufacturing Company Polymerized microemulsion pressure sensitive adhesive compositions and methods of preparing and using same
US5476664A (en) 1994-04-15 1995-12-19 Leonard Bloom Treatment of warts using anthralins and occlusion
US5968533A (en) 1994-11-15 1999-10-19 Porter; Steven S. Skin care compositions and methods
AU4282096A (en) 1994-11-15 1996-06-06 Osmotics Corporation Skin care compositions and methods
US5559165A (en) 1995-08-08 1996-09-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for bonding to sensitive areas of the human body
US5571096A (en) 1995-09-19 1996-11-05 The Procter & Gamble Company Absorbent article having breathable side panels
JP2935343B2 (ja) 1996-03-04 1999-08-16 花王株式会社 シート状パック
JPH09295929A (ja) 1996-05-02 1997-11-18 宰賢 ▲べ▼ 皮膚皺除去用皮膚粘着型化粧料及びその製造方法
GR1002807B (el) 1996-06-20 1997-11-13 Lavipharm A.E. Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του
US6338855B1 (en) 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
US5972359A (en) 1997-05-23 1999-10-26 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
US6180133B1 (en) 1997-11-25 2001-01-30 Watson Pharmaceuticals, Inc. Antioxidant composition for topical/transdermal prevention and treatment of wrinkles
US5958447A (en) 1998-03-17 1999-09-28 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6325565B1 (en) 1998-06-30 2001-12-04 The Procter & Gamble Company Anti-perspirant/deodorant applicator
DE19830649C2 (de) 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
US6221369B1 (en) 1998-09-03 2001-04-24 Dan B. Pool Human skin care product and method
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
FR2784581B1 (fr) 1998-10-20 2002-12-13 Oreal Patch, ensemble constitue d'un patch et d'un recipient, et procede
US6162458A (en) 1998-11-17 2000-12-19 Nagaoka & Co., Ltd. Patch for beautification
DE69930297T2 (de) 1998-11-24 2006-11-30 Johnson & Johnson Consumer Companies, Inc. Beschichtung auf wundverbänden und bandagen als träger für einen wirkstoff
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US7063859B1 (en) 1999-04-28 2006-06-20 Noven Pharmaceuticals, Inc. Barrier film lined backing layer composition and method for topical administration of active agents
US6277401B1 (en) 1999-05-07 2001-08-21 U.S. Dermatologics, Inc. Drug delivery device
FI112587B (fi) 1999-06-04 2003-12-31 Eriksson Capital Ab Kestomakkaran polymeerisuoli, menetelmä kestomakkaran valmistamiseksi ja polymeerisuolen käyttö kestomakkaroiden valmistuksessa
USD440315S1 (en) 1999-06-18 2001-04-10 The Procter & Gamble Company Eye wrinkle treatment pad
WO2001001951A1 (fr) 1999-07-06 2001-01-11 The Procter & Gamble Company Dispositifs
AU3246000A (en) 1999-07-06 2001-01-22 Procter & Gamble Company, The Cosmetic or dermapharmaceutical patch
US6495229B1 (en) 1999-09-17 2002-12-17 Avery Dennison Corporation Pattern coated adhesive article
US6926960B1 (en) 1999-11-05 2005-08-09 Kao Corporation Adhesive cleaning sheet
US6168028B1 (en) 1999-11-19 2001-01-02 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Packaged skin product
US20030072724A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition to treat hyperpigmentation of the skin
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20020077266A1 (en) 2000-04-08 2002-06-20 Gabriel Flor Gutierrez Portable stain removal product
US7658942B2 (en) 2000-04-12 2010-02-09 The Procter & Gamble Company Cosmetic devices
ES2278603T3 (es) 2000-04-12 2007-08-16 THE PROCTER & GAMBLE COMPANY Dispositivos en forma de lamina formados previamente adecuados para aplicacion topica.
US20020022040A1 (en) * 2000-07-10 2002-02-21 The Proctor & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
JP2002076432A (ja) 2000-08-30 2002-03-15 Stanley Electric Co Ltd 端面発光型半導体装置、その製造方法及び光空間伝送装置
DE10056010A1 (de) 2000-11-11 2002-05-16 Beiersdorf Ag Pflaster mit hautpflegenden Substanzen
US6448303B1 (en) 2000-12-29 2002-09-10 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for dermal application
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US20050013784A1 (en) 2001-02-08 2005-01-20 The Procter & Gamble Company Mask composition
JP2002249422A (ja) 2001-02-23 2002-09-06 Fumio Kamiyama スキンケア用貼付剤
US20020187181A1 (en) * 2001-05-14 2002-12-12 3M Innovative Properties Company System for delivering cosmetics and pharmaceuticals
US20030082219A1 (en) 2001-10-01 2003-05-01 The Procter & Gamble Company Skin care compositions comprising low concentrations of skin treatment agents
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
JP4157840B2 (ja) 2001-12-11 2008-10-01 ザ プロクター アンド ギャンブル カンパニー 予備成形物の作製プロセス
USD484985S1 (en) 2001-12-28 2004-01-06 Hisamitsu Pharmaceutical Co., Inc. Sheet for cooling human body
US20030152610A1 (en) 2002-01-28 2003-08-14 David Rolf Cosmetic patch
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20030175328A1 (en) 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
US20030175333A1 (en) 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
US20030180347A1 (en) 2002-03-19 2003-09-25 W.F. Young, Incorporated Patch for the delivery of topical agents
DE10212864B4 (de) 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US6706775B2 (en) 2002-04-02 2004-03-16 H. H. Brown Shoe Technologies, Inc. Polyurethane foam products with controlled release of agents and additives
JP2004051516A (ja) 2002-07-18 2004-02-19 Kanebo Ltd シート状パック
BR0312679A (pt) 2002-07-19 2005-04-26 Procter & Gamble Composição de máscara contendo composição lìquida emulsificada
US20040101494A1 (en) * 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20040115137A1 (en) * 2002-12-17 2004-06-17 Verrall Andrew P. Water-soluble film for oral administration
US20040116018A1 (en) 2002-12-17 2004-06-17 Kimberly-Clark Worldwide, Inc. Method of making fibers, nonwoven fabrics, porous films and foams that include skin treatment additives
US7887842B2 (en) 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
WO2004077990A1 (fr) 2003-03-07 2004-09-16 Aerotech Australia Pty Ltd Dispositif destine a traiter un tissu cutane
US7479132B2 (en) 2003-03-10 2009-01-20 Tokuyama Corporation Patch material for ionic medicine administration
JP4795962B2 (ja) * 2003-05-28 2011-10-19 モノソル・アールエックス・エルエルシー ポリエチレンオキシドフィルムおよびそれからなる薬物送達系
BRPI0411333A (pt) 2003-06-11 2006-07-25 Procter & Gamble dispositivo de preparação para uso compreendendo um produto hidrogel pré-formado
AU2004257173B2 (en) 2003-07-07 2009-12-10 Dow Global Technologies Inc. Thin foamed polyethylene sheets
US7758878B2 (en) 2003-10-10 2010-07-20 Access Business Group International Llc Cosmetic treatment system and methods
ES2426990T3 (es) * 2003-10-24 2013-10-28 Adhesives Research, Inc. Películas desintegrables para dispositivos de diagnóstico
WO2005051333A1 (fr) 2003-11-28 2005-06-09 Coloplast A/S Bande adhesive
US20060177487A1 (en) 2005-02-07 2006-08-10 Christine Martz Moisture and lotion retainer
DE102004009903A1 (de) 2004-02-26 2005-09-22 Grünenthal GmbH Pflaster mit reduzierter Hautirritation
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US20050266059A1 (en) 2004-05-26 2005-12-01 Poss Valerie S Heel moisturizing patch
JP2006021789A (ja) 2004-07-07 2006-01-26 Kao Corp 容器起立機能付き箱
USD519239S1 (en) 2004-11-01 2006-04-18 Ayako Katagiri Cosmetic device
JP5025268B2 (ja) 2004-11-10 2012-09-12 久光製薬株式会社 外用製剤及び貼付剤
US20060104931A1 (en) 2004-11-12 2006-05-18 Takeshi Fukutome Cosmetic treatment article comprising substrate and gel composition
JP4758434B2 (ja) 2004-11-12 2011-08-31 ザ プロクター アンド ギャンブル カンパニー 下層形状に適合可能なトリートメント物品
EP1827400A2 (fr) 2004-11-22 2007-09-05 Nu-Tein Co., Inc. Patch topique pour la peau contenant des xanthophylles
US20060188558A1 (en) 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
US20070020220A1 (en) 2005-04-27 2007-01-25 Procter & Gamble Personal care compositions
WO2007016265A2 (fr) 2005-07-28 2007-02-08 Hollister Incorporated Compositions d'adhesif autocollant et pansements auto-adherents les comprenant
KR100663163B1 (ko) 2005-10-24 2007-01-02 (주)아모레퍼시픽 비스테로이드성 소염진통제를 함유하는 경피 투여 제제
CN101641079A (zh) * 2006-03-13 2010-02-03 宝洁公司 组合施加能量和局部用组合物以调节哺乳动物皮肤状况
US20070259029A1 (en) 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
DE102006026578B4 (de) 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
JP2009541301A (ja) * 2006-07-14 2009-11-26 ザ プロクター アンド ギャンブル カンパニー 集中ケア及び全体的トリートメントを同時に送達することができるトリートメント物品
JP4943960B2 (ja) 2006-07-19 2012-05-30 三菱樹脂株式会社 積層シート状物
KR20080014461A (ko) 2006-08-11 2008-02-14 쓰리엠 이노베이티브 프로퍼티즈 캄파니 경피투여형 화장료 패치
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
DE102006047229A1 (de) 2006-10-04 2008-04-10 Henkel Kgaa Wasch- oder Reinigungsmittelabgabesystem
DE102006058649B4 (de) 2006-12-11 2011-01-20 Beiersdorf Ag Ultraschallpflaster und dessen Verwendung zur Hautfaltenreduktion
US20080200591A1 (en) 2007-02-15 2008-08-21 Isao Noda Melt Processable Reactive Pellets Capable of Forming Ester Condensates and Process for Forming Melt Processable Reactive Pellets
ITMI20070798A1 (it) 2007-04-18 2008-10-19 Biofarmitalia Spa Dispositivo per distendere le rughe della pelle umana
KR100871282B1 (ko) 2007-06-22 2008-11-28 김정현 안면 주름개선용 미용패드
US20090010998A1 (en) * 2007-07-03 2009-01-08 Marchitto Kevin S Drug-delivery patch comprising a dissolvable layer and uses thereof
WO2009055048A1 (fr) 2007-10-24 2009-04-30 Bio Med Sciences, Inc. Timbre cutané d'atténuation de rides, procédé de fabrication et objets utiles apparentés
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
CN102066101A (zh) 2008-06-20 2011-05-18 宝洁公司 泡沫薄膜包装
US20100239619A1 (en) 2009-03-20 2010-09-23 Marni Markell Hurwitz Semi-permanent color for application to the skin and applicators therefor
EP2316436A1 (fr) 2009-10-30 2011-05-04 Johnson & Johnson GmbH Bande, en particulier une bande adhésive, pour le traitement des troubles de la peau comportant un film, en particulier un film pouvant être dissous, et contenant au moins une enzyme
EP2316438A1 (fr) 2009-10-30 2011-05-04 Johnson & Johnson GmbH Bande, en particulier une bande adhésive, pour le traitement des troubles de la peau comportant au moins un inhibiteur d'hyperkératose et/ou au moins un agent kératolytique
BR112012020661A2 (pt) 2010-02-17 2016-07-26 Procter & Gamble artigo para cuidados pessoais flexível
JP2011178693A (ja) 2010-02-26 2011-09-15 Kose Corp 美容方法
US20110300198A1 (en) 2010-06-03 2011-12-08 Amos Nussinovitch Hydrocolloid - essential oil patches
CA2809885A1 (fr) * 2010-12-22 2012-06-28 Avon Products, Inc. Films cosmetiques
US20120308619A1 (en) 2011-06-03 2012-12-06 Tousley Catherine L B Cosmetic anti-wrinkle patch
EP2559425A1 (fr) 2011-08-17 2013-02-20 The Procter & Gamble Company Procédé d'épilation et kit
PL2561856T3 (pl) 2011-08-24 2018-03-30 The Procter And Gamble Company Sposób i zestaw do depilacji
AU2011376960B2 (en) * 2011-09-14 2015-10-29 Colgate-Palmolive Company Tooth whitening strip
US9949897B2 (en) 2012-04-11 2018-04-24 L'oreal Self-standing cosmetic sheet
DE102012108705B4 (de) 2012-09-17 2020-01-09 Mondi Ag Kunststofffolie
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
US9877874B2 (en) 2012-11-21 2018-01-30 Coloplast A/S Adhesive dressing
US11311423B2 (en) 2012-12-19 2022-04-26 Nichiban Co., Ltd. Facial patch
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
US20140377512A1 (en) 2013-06-24 2014-12-25 The Procter & Gamble Company Printed Foamed Film Packaging
US20140376835A1 (en) 2013-06-24 2014-12-25 The Procter & Gamble Company Foamed Film Packaging
WO2015161481A1 (fr) 2014-04-24 2015-10-29 The Procter & Gamble Company Sac fabriqué à partir d'une structure multicouche de film mousse
JP6513800B2 (ja) 2014-10-21 2019-05-15 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するためのキット
WO2017070078A1 (fr) 2015-10-22 2017-04-27 The Procter & Gamble Company Timbre barrière d'un film expansé et procédés d'amélioration de l'aspect de la peau
EP3364936B1 (fr) 2015-10-22 2019-11-20 The Procter and Gamble Company Timbre barrière d'un film expansé et procédés pour améliorer l'aspect de la peau
US10272018B2 (en) 2015-10-22 2019-04-30 The Procter & Gamble Company Barrier patch of a foamed film and methods of improving skin appearance
WO2018129496A1 (fr) 2017-01-09 2018-07-12 The Procter & Gamble Company Timbre barrière comportant un film soluble et procédés pour améliorer l'aspect de la peau
US10751265B2 (en) 2017-01-09 2020-08-25 The Procter & Gamble Barrier patch with soluble film and methods of improving skin appearance
US10857076B2 (en) * 2017-01-09 2020-12-08 The Procter & Gamble Company Barrier patch with soluble film and methods of improving skin appearance
CN110769945B (zh) 2017-06-22 2023-01-24 宝洁公司 包括水溶性层和气相沉积涂层的美容护理品膜
US10751266B2 (en) 2018-03-19 2020-08-25 The Procter & Gamble Company Method of making a barrier patch with soluble film

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
CN110049803A (zh) 2019-07-23
US10806681B2 (en) 2020-10-20
US20180200158A1 (en) 2018-07-19
US10799431B2 (en) 2020-10-13
CN110167642A (zh) 2019-08-23
WO2018129496A1 (fr) 2018-07-12
CN110049803B (zh) 2022-06-07
CN110167642B (zh) 2022-06-07
EP3565641A1 (fr) 2019-11-13
EP3565642A1 (fr) 2019-11-13
JP6974922B2 (ja) 2021-12-01
US20180193230A1 (en) 2018-07-12
JP2020515509A (ja) 2020-05-28
WO2018129495A1 (fr) 2018-07-12

Similar Documents

Publication Publication Date Title
EP3565641B1 (fr) Patch formant barrière à film soluble et méthodes permettant d'améliorer l'aspect de la peau
US10857076B2 (en) Barrier patch with soluble film and methods of improving skin appearance
US10751265B2 (en) Barrier patch with soluble film and methods of improving skin appearance
EP3641952B1 (fr) Films de masques de beauté comprenant une couche hydrosoluble et un revêtement déposé par évaporation sous vide
EP3768249B1 (fr) Procédé de fabrication d'un timbre barrière à film soluble
EP3364936B1 (fr) Timbre barrière d'un film expansé et procédés pour améliorer l'aspect de la peau
EP3364935B1 (fr) Timbre barrière d'un film expansé et procédés pour améliorer l'aspect de la peau
EP3365066B1 (fr) Timbre barrière d'un film expansé et procédés d'amélioration de l'aspect de la peau

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210125

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018018964

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 1403789

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210923

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1403789

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210924

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210923

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018018964

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220109

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230429

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231130

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231212

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210623

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231205

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180109